Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:26:01 EST Tue 04 Nov 2025
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q3.2120.16·120.290.1120.22-1.83-1.51,137.6137,12712,150123.15  123.15  119.24124.61  86.0810:08:02Nov 0315 min RT 2¢

Recent Trades - Last 10 of 12150
Time ETExPriceChangeVolume
10:08:12Q120.1799-1.87011,414
10:08:12Q120.17-1.8810
10:08:12Q120.17-1.8837
10:08:12Q120.18-1.8716
10:08:12Q120.18-1.878
10:08:12Q120.18-1.8710
10:08:12Q120.17-1.8820
10:08:12Q120.20-1.851
10:08:12Q120.20-1.8599
10:08:11Q120.135-1.9152

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-03 09:10U:GILDNews ReleaseGilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
2025-10-31 08:00U:GILDNews ReleaseGilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo(TM) (Lenacapavir)
2025-10-30 16:02U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2025 Financial Results
2025-10-23 08:00U:GILDNews ReleaseGilead to Showcase Interim Long-Term Efficacy Data for Livdelzi(TM) (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
2025-10-19 08:30U:GILDNews ReleaseGilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
2025-10-19 02:30U:GILDNews ReleaseTrodelvy(TM) Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
2025-10-15 03:30U:GILDNews ReleaseGilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention
2025-10-13 08:30U:GILDNews ReleaseGilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
2025-10-09 16:05U:GILDNews ReleaseGilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
2025-09-25 08:00U:GILDNews ReleaseGilead Foundation Grants $6.5 Million in Commitment to STEM Education
2025-09-04 14:15U:GILDNews ReleaseGilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
2025-09-04 08:30U:GILDNews ReleaseGilead Sciences Launches Choose U(TM) Campaign Spotlighting the Inspiring Experiences of People Living with HIV
2025-09-03 11:30U:GILDNews ReleaseGilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
2025-08-26 03:00U:GILDNews ReleaseEuropean Commission Authorizes Twice-Yearly Yeytuo(TM) (Lenacapavir) for HIV Prevention
2025-08-21 08:30U:GILDNews ReleaseKite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
2025-08-20 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-08-07 16:02U:GILDNews ReleaseGilead Sciences Announces Second Quarter 2025 Financial Results
2025-07-25 03:00U:GILDNews ReleaseGilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
2025-07-24 16:05U:GILDNews ReleaseGilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
2025-07-23 10:15U:GILDNews ReleaseLooking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic